uploads/2018/10/Chart-02-9-1.jpg

Analysts Expect Incyte to Report Revenue Growth in Third Quarter

By

Updated

Incyte’s Q3 2018 revenue estimates

As discussed earlier, analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018. The below graph compares the revenues of Incyte since the first quarter of 2017 and estimates for the third quarter of 2018. Incyte’s revenue stream includes product sales, royalty revenues, and other revenues from collaborations. The estimates for the third quarter of 2018 are as follows.

Article continues below advertisement

Product sales

The product portfolio includes two products, Jakafi and Iclusig. The revenues for both these products are expected to see growth during the third quarter of 2018, following strong sales in US markets. Incyte acquired the commercial rights for Iclusig from Ariad Pharmaceuticals in 2016.

Royalty revenues

Incyte receives royalties for Jakafi from Novartis and for Olumiant from Eli Lilly (LLY). Novartis (NVS) holds the license for development and commercialization of Jakafi outside the US and markets the drug as Jakavi. The royalty revenues from Jakavi sales are expected to see growth during the quarter. Eli Lilly (LLY) commercializes Olumiant (baricitinib) worldwide, and Incyte receives royalties for the sales of Olumiant. The royalty revenues from sales of Olumiant are expected to see growth during the quarter.

Other revenues

Incyte has some collaborative research and license agreements with Novartis and Eli Lilly. The contract revenues are related to milestone payments for the development of drugs under these agreements. These revenues are not included in the estimates above.

The First Trust NYSE Arca Biotechnology ETF (FBT) holds 3.4% of its total investments in Incyte (INCY), 3.4% in Bluebird Bio (BLUE), 3.4% in Gilead Sciences (GILD), and 3.3% in Celgene (CELG).

Advertisement

More From Market Realist